0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Alpha 1 Antitrypsin Deficiency Treatment Market Research Report 2023
Published Date: January 2023
|
Report Code: QYRE-Auto-2X9559
Home | Market Reports | Health| Health Conditions| Respiratory Conditions
Global Alpha 1 Antitrypsin Deficiency Treatment Market Insights and Forecast to 2028
BUY CHAPTERS

Global Alpha 1 Antitrypsin Deficiency Treatment Market Research Report 2023

Code: QYRE-Auto-2X9559
Report
January 2023
Pages:94
QYResearch
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Global Alpha 1 Antitrypsin Deficiency Treatment Market

Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.
The global Alpha 1 Antitrypsin Deficiency Treatment market was valued at US$ 2042.3 million in 2022 and is anticipated to reach US$ 3425.1 million by 2029, witnessing a CAGR of 9.0% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Global players of Alpha 1 Antitrypsin Deficiency Treatment include Pfizer, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceutical Industries, Takeda, Baxter, Grifols, CSL Behring and Kamada Ltd, etc. Top five players occupy for share about 28%. United States is the largest market, with a share about 37%, followed by European Union and China. In terms of product, Augmentation Therapy is the largest segment, with a share over 44%.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Alpha 1 Antitrypsin Deficiency Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Alpha 1 Antitrypsin Deficiency Treatment.
The Alpha 1 Antitrypsin Deficiency Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Alpha 1 Antitrypsin Deficiency Treatment market comprehensively. Regional market sizes, concerning products by indication, by end users, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Alpha 1 Antitrypsin Deficiency Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by indication, by end users, and by regions.

Key Segmentations

By Company

  • Pfizer
  • GlaxoSmithKline
  • AstraZeneca
  • Boehringer Ingelheim
  • Teva Pharmaceutical Industries
  • Takeda
  • Baxter
  • Grifols
  • CSL Behring
  • Kamada Ltd
  • Chiesi Pharmaceuticals
  • Kedrion Group
  • Vertex Pharmaceuticals
  • ProMetic Life Sciences

Segment by Indication

  • Augmentation Therapy
  • Cystic Fibrosis(CF)
  • Non-CF Bronchiectasis(NCFB)
  • Diabetes
  • Other

Segment by End Users

  • COPD
  • Cystic Fibrosis(CF)
  • Non-CF Bronchiectasis(NCFB)
  • Diabetes

By Region

  • North America
  • United States
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Russia
  • Nordic Countries
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia
  • Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
  • Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by indication, end users, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Alpha 1 Antitrypsin Deficiency Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by indication, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by end users, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

Scope of Global Alpha 1 Antitrypsin Deficiency Treatment Market Report

Report MetricDetails
Report NameGlobal Alpha 1 Antitrypsin Deficiency Treatment Market
Base Year2022
Forecasted years2023-2029
Forecast unitsUSD
Report coverageRevenue and volume forecast, company share, competitive landscape, growth factors and trends
Geographic regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East & Africa
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Indication
1.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Indication: 2018 VS 2022 VS 2029
1.2.2 Augmentation Therapy
1.2.3 Cystic Fibrosis(CF)
1.2.4 Non-CF Bronchiectasis(NCFB)
1.2.5 Diabetes
1.2.6 Other
1.3 Market by End Users
1.3.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Growth by End Users: 2018 VS 2022 VS 2029
1.3.2 COPD
1.3.3 Cystic Fibrosis(CF)
1.3.4 Non-CF Bronchiectasis(NCFB)
1.3.5 Diabetes
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Perspective (2018-2029)
2.2 Alpha 1 Antitrypsin Deficiency Treatment Growth Trends by Region
2.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by Region (2018-2023)
2.2.3 Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Region (2024-2029)
2.3 Alpha 1 Antitrypsin Deficiency Treatment Market Dynamics
2.3.1 Alpha 1 Antitrypsin Deficiency Treatment Industry Trends
2.3.2 Alpha 1 Antitrypsin Deficiency Treatment Market Drivers
2.3.3 Alpha 1 Antitrypsin Deficiency Treatment Market Challenges
2.3.4 Alpha 1 Antitrypsin Deficiency Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Revenue
3.1.1 Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Revenue (2018-2023)
3.1.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Alpha 1 Antitrypsin Deficiency Treatment Revenue
3.4 Global Alpha 1 Antitrypsin Deficiency Treatment Market Concentration Ratio
3.4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Alpha 1 Antitrypsin Deficiency Treatment Revenue in 2022
3.5 Alpha 1 Antitrypsin Deficiency Treatment Key Players Head office and Area Served
3.6 Key Players Alpha 1 Antitrypsin Deficiency Treatment Product Solution and Service
3.7 Date of Enter into Alpha 1 Antitrypsin Deficiency Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Alpha 1 Antitrypsin Deficiency Treatment Breakdown Data by Indication
4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by Indication (2018-2023)
4.2 Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Indication (2024-2029)
5 Alpha 1 Antitrypsin Deficiency Treatment Breakdown Data by End Users
5.1 Global Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by End Users (2018-2023)
5.2 Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by End Users (2024-2029)
6 North America
6.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size (2018-2029)
6.2 North America Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2018-2023)
6.4 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size (2018-2029)
7.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2018-2023)
7.4 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size (2018-2029)
8.2 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size (2018-2029)
9.2 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2018-2023)
9.4 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size (2018-2029)
10.2 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.1.4 Pfizer Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
11.1.5 Pfizer Recent Development
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Detail
11.2.2 GlaxoSmithKline Business Overview
11.2.3 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.2.4 GlaxoSmithKline Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
11.2.5 GlaxoSmithKline Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Detail
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.3.4 AstraZeneca Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
11.3.5 AstraZeneca Recent Development
11.4 Boehringer Ingelheim
11.4.1 Boehringer Ingelheim Company Detail
11.4.2 Boehringer Ingelheim Business Overview
11.4.3 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.4.4 Boehringer Ingelheim Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
11.4.5 Boehringer Ingelheim Recent Development
11.5 Teva Pharmaceutical Industries
11.5.1 Teva Pharmaceutical Industries Company Detail
11.5.2 Teva Pharmaceutical Industries Business Overview
11.5.3 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.5.4 Teva Pharmaceutical Industries Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
11.5.5 Teva Pharmaceutical Industries Recent Development
11.6 Takeda
11.6.1 Takeda Company Detail
11.6.2 Takeda Business Overview
11.6.3 Takeda Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.6.4 Takeda Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
11.6.5 Takeda Recent Development
11.7 Baxter
11.7.1 Baxter Company Detail
11.7.2 Baxter Business Overview
11.7.3 Baxter Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.7.4 Baxter Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
11.7.5 Baxter Recent Development
11.8 Grifols
11.8.1 Grifols Company Detail
11.8.2 Grifols Business Overview
11.8.3 Grifols Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.8.4 Grifols Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
11.8.5 Grifols Recent Development
11.9 CSL Behring
11.9.1 CSL Behring Company Detail
11.9.2 CSL Behring Business Overview
11.9.3 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.9.4 CSL Behring Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
11.9.5 CSL Behring Recent Development
11.10 Kamada Ltd
11.10.1 Kamada Ltd Company Detail
11.10.2 Kamada Ltd Business Overview
11.10.3 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.10.4 Kamada Ltd Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
11.10.5 Kamada Ltd Recent Development
11.11 Chiesi Pharmaceuticals
11.11.1 Chiesi Pharmaceuticals Company Detail
11.11.2 Chiesi Pharmaceuticals Business Overview
11.11.3 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.11.4 Chiesi Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
11.11.5 Chiesi Pharmaceuticals Recent Development
11.12 Kedrion Group
11.12.1 Kedrion Group Company Detail
11.12.2 Kedrion Group Business Overview
11.12.3 Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.12.4 Kedrion Group Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
11.12.5 Kedrion Group Recent Development
11.13 Vertex Pharmaceuticals
11.13.1 Vertex Pharmaceuticals Company Detail
11.13.2 Vertex Pharmaceuticals Business Overview
11.13.3 Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.13.4 Vertex Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
11.13.5 Vertex Pharmaceuticals Recent Development
11.14 ProMetic Life Sciences
11.14.1 ProMetic Life Sciences Company Detail
11.14.2 ProMetic Life Sciences Business Overview
11.14.3 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Introduction
11.14.4 ProMetic Life Sciences Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
11.14.5 ProMetic Life Sciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
    Table 1. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Indication (US$ Million): 2018 VS 2022 VS 2029
    Table 2. Key Players of Augmentation Therapy
    Table 3. Key Players of Cystic Fibrosis(CF)
    Table 4. Key Players of Non-CF Bronchiectasis(NCFB)
    Table 5. Key Players of Diabetes
    Table 6. Key Players of Other
    Table 7. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth by End Users (US$ Million): 2018 VS 2022 VS 2029
    Table 8. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 9. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2018-2023) & (US$ Million)
    Table 10. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region (2018-2023)
    Table 11. Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Region (2024-2029) & (US$ Million)
    Table 12. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region (2024-2029)
    Table 13. Alpha 1 Antitrypsin Deficiency Treatment Market Trends
    Table 14. Alpha 1 Antitrypsin Deficiency Treatment Market Drivers
    Table 15. Alpha 1 Antitrypsin Deficiency Treatment Market Challenges
    Table 16. Alpha 1 Antitrypsin Deficiency Treatment Market Restraints
    Table 17. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Players (2018-2023) & (US$ Million)
    Table 18. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Players (2018-2023)
    Table 19. Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alpha 1 Antitrypsin Deficiency Treatment as of 2022)
    Table 20. Ranking of Global Top Alpha 1 Antitrypsin Deficiency Treatment Companies by Revenue (US$ Million) in 2022
    Table 21. Global 5 Largest Players Market Share by Alpha 1 Antitrypsin Deficiency Treatment Revenue (CR5 and HHI) & (2018-2023)
    Table 22. Key Players Headquarters and Area Served
    Table 23. Key Players Alpha 1 Antitrypsin Deficiency Treatment Product Solution and Service
    Table 24. Date of Enter into Alpha 1 Antitrypsin Deficiency Treatment Market
    Table 25. Mergers & Acquisitions, Expansion Plans
    Table 26. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication (2018-2023) & (US$ Million)
    Table 27. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Indication (2018-2023)
    Table 28. Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Indication (2024-2029) & (US$ Million)
    Table 29. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Indication (2024-2029)
    Table 30. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2018-2023) & (US$ Million)
    Table 31. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by End Users (2018-2023)
    Table 32. Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by End Users (2024-2029) & (US$ Million)
    Table 33. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by End Users (2024-2029)
    Table 34. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 35. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2018-2023) & (US$ Million)
    Table 36. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2024-2029) & (US$ Million)
    Table 37. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 38. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2018-2023) & (US$ Million)
    Table 39. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2024-2029) & (US$ Million)
    Table 40. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 41. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2018-2023) & (US$ Million)
    Table 42. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2024-2029) & (US$ Million)
    Table 43. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 44. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2018-2023) & (US$ Million)
    Table 45. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2024-2029) & (US$ Million)
    Table 46. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 47. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2018-2023) & (US$ Million)
    Table 48. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2024-2029) & (US$ Million)
    Table 49. Pfizer Company Detail
    Table 50. Pfizer Business Overview
    Table 51. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Product
    Table 52. Pfizer Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
    Table 53. Pfizer Recent Development
    Table 54. GlaxoSmithKline Company Detail
    Table 55. GlaxoSmithKline Business Overview
    Table 56. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Product
    Table 57. GlaxoSmithKline Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
    Table 58. GlaxoSmithKline Recent Development
    Table 59. AstraZeneca Company Detail
    Table 60. AstraZeneca Business Overview
    Table 61. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Product
    Table 62. AstraZeneca Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
    Table 63. AstraZeneca Recent Development
    Table 64. Boehringer Ingelheim Company Detail
    Table 65. Boehringer Ingelheim Business Overview
    Table 66. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Product
    Table 67. Boehringer Ingelheim Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
    Table 68. Boehringer Ingelheim Recent Development
    Table 69. Teva Pharmaceutical Industries Company Detail
    Table 70. Teva Pharmaceutical Industries Business Overview
    Table 71. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Product
    Table 72. Teva Pharmaceutical Industries Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
    Table 73. Teva Pharmaceutical Industries Recent Development
    Table 74. Takeda Company Detail
    Table 75. Takeda Business Overview
    Table 76. Takeda Alpha 1 Antitrypsin Deficiency Treatment Product
    Table 77. Takeda Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
    Table 78. Takeda Recent Development
    Table 79. Baxter Company Detail
    Table 80. Baxter Business Overview
    Table 81. Baxter Alpha 1 Antitrypsin Deficiency Treatment Product
    Table 82. Baxter Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
    Table 83. Baxter Recent Development
    Table 84. Grifols Company Detail
    Table 85. Grifols Business Overview
    Table 86. Grifols Alpha 1 Antitrypsin Deficiency Treatment Product
    Table 87. Grifols Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
    Table 88. Grifols Recent Development
    Table 89. CSL Behring Company Detail
    Table 90. CSL Behring Business Overview
    Table 91. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Product
    Table 92. CSL Behring Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
    Table 93. CSL Behring Recent Development
    Table 94. Kamada Ltd Company Detail
    Table 95. Kamada Ltd Business Overview
    Table 96. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Product
    Table 97. Kamada Ltd Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
    Table 98. Kamada Ltd Recent Development
    Table 99. Chiesi Pharmaceuticals Company Detail
    Table 100. Chiesi Pharmaceuticals Business Overview
    Table 101. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product
    Table 102. Chiesi Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
    Table 103. Chiesi Pharmaceuticals Recent Development
    Table 104. Kedrion Group Company Detail
    Table 105. Kedrion Group Business Overview
    Table 106. Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Product
    Table 107. Kedrion Group Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
    Table 108. Kedrion Group Recent Development
    Table 109. Vertex Pharmaceuticals Company Detail
    Table 110. Vertex Pharmaceuticals Business Overview
    Table 111. Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product
    Table 112. Vertex Pharmaceuticals Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
    Table 113. Vertex Pharmaceuticals Recent Development
    Table 114. ProMetic Life Sciences Company Detail
    Table 115. ProMetic Life Sciences Business Overview
    Table 116. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Product
    Table 117. ProMetic Life Sciences Revenue in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023) & (US$ Million)
    Table 118. ProMetic Life Sciences Recent Development
    Table 119. Research Programs/Design for This Report
    Table 120. Key Data Information from Secondary Sources
    Table 121. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Comparison by Indication (2023-2029) & (US$ Million)
    Figure 2. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Indication: 2022 VS 2029
    Figure 3. Augmentation Therapy Features
    Figure 4. Cystic Fibrosis(CF) Features
    Figure 5. Non-CF Bronchiectasis(NCFB) Features
    Figure 6. Diabetes Features
    Figure 7. Other Features
    Figure 8. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Comparison by End Users (2023-2029) & (US$ Million)
    Figure 9. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by End Users: 2022 VS 2029
    Figure 10. COPD Case Studies
    Figure 11. Cystic Fibrosis(CF) Case Studies
    Figure 12. Non-CF Bronchiectasis(NCFB) Case Studies
    Figure 13. Diabetes Case Studies
    Figure 14. Alpha 1 Antitrypsin Deficiency Treatment Report Years Considered
    Figure 15. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size (US$ Million), Year-over-Year: 2018-2029
    Figure 16. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, (US$ Million), 2018 VS 2022 VS 2029
    Figure 17. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region: 2022 VS 2029
    Figure 18. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Players in 2022
    Figure 19. Global Top Alpha 1 Antitrypsin Deficiency Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alpha 1 Antitrypsin Deficiency Treatment as of 2022)
    Figure 20. The Top 10 and 5 Players Market Share by Alpha 1 Antitrypsin Deficiency Treatment Revenue in 2022
    Figure 21. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 22. North America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2018-2029)
    Figure 23. United States Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 24. Canada Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 25. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 26. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2018-2029)
    Figure 27. Germany Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 28. France Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 29. U.K. Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 30. Italy Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 31. Russia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 32. Nordic Countries Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 33. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 34. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region (2018-2029)
    Figure 35. China Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 36. Japan Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 37. South Korea Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 38. Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 39. India Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 40. Australia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 41. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 42. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2018-2029)
    Figure 43. Mexico Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 44. Brazil Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 45. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 46. Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2018-2029)
    Figure 47. Turkey Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 48. Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 49. Pfizer Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
    Figure 50. GlaxoSmithKline Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
    Figure 51. AstraZeneca Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
    Figure 52. Boehringer Ingelheim Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
    Figure 53. Teva Pharmaceutical Industries Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
    Figure 54. Takeda Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
    Figure 55. Baxter Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
    Figure 56. Grifols Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
    Figure 57. CSL Behring Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
    Figure 58. Kamada Ltd Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
    Figure 59. Chiesi Pharmaceuticals Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
    Figure 60. Kedrion Group Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
    Figure 61. Vertex Pharmaceuticals Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
    Figure 62. ProMetic Life Sciences Revenue Growth Rate in Alpha 1 Antitrypsin Deficiency Treatment Business (2018-2023)
    Figure 63. Bottom-up and Top-down Approaches for This Report
    Figure 64. Data Triangulation
    Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (10% Discount)

OUR CUSTOMER

Accenture

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Expiratory Filter Market Research Report 2023

120 Pages
Type: Report
Code: QYRE-Auto-2K12996
Mon Jan 23 00:00:00 UTC 2023

Add to Cart

Global Airway Mucus Clearance Device Market Research Report 2023

120 Pages
Type: Report
Code: QYRE-Auto-0T12229
Fri Jan 20 00:00:00 UTC 2023

Add to Cart

Global Automatic Continuous Positive Airway Pressure Market Research Report 2023

120 Pages
Type: Report
Code: QYRE-Auto-18O13072
Tue Jan 17 00:00:00 UTC 2023

Add to Cart

Global Fully Automatic Bilevel Ventilator Market Research Report 2023

120 Pages
Type: Report
Code: QYRE-Auto-4W13211
Tue Jan 17 00:00:00 UTC 2023

Add to Cart